Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/- Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets.

Gide, Tuba N; Pires da Silva, Inês; Quek, Camelia; Ferguson, Peter M; Batten, Marcel; Shang, Ping; Ahmed, Tasnia; Menzies, Alexander M; Carlino, Matteo S; Saw, Robyn P M; Thompson, John F; Scolyer, Richard A; Long, Georgina V; Wilmott, James S

Gide, Tuba N; Pires da Silva, Inês; Quek, Camelia; Ferguson, Peter M; Batten, Marcel; Shang, Ping; Ahmed, Tasnia; Menzies, Alexander M; Carlino, Matteo S; Saw, Robyn P M; Thompson, John F; Scolyer, Richard A; Long, Georgina V; Wilmott, James S.

Gide TN; Melanoma Institute Australia, The University of Sydney, Sydney, NSW 2065, Australia.
Pires da Silva I; Charles Perkins Centre, The University of Sydney, Sydney, NSW 2006, Australia.
Quek C; Sydney Medical School, The University of Sydney, Sydney, NSW 2006, Australia.
Ferguson PM; Melanoma Institute Australia, The University of Sydney, Sydney, NSW 2065, Australia.
Batten M; Charles Perkins Centre, The University of Sydney, Sydney, NSW 2006, Australia.
Shang P; Sydney Medical School, The University of Sydney, Sydney, NSW 2006, Australia.
Ahmed T; Melanoma Institute Australia, The University of Sydney, Sydney, NSW 2065, Australia.
Menzies AM; Charles Perkins Centre, The University of Sydney, Sydney, NSW 2006, Australia.
Carlino MS; Sydney Medical School, The University of Sydney, Sydney, NSW 2006, Australia.
Saw RPM; Melanoma Institute Australia, The University of Sydney, Sydney, NSW 2065, Australia.
Thompson JF; Sydney Medical School, The University of Sydney, Sydney, NSW 2006, Australia.
Scolyer RA; NSW Health Pathology, Sydney, NSW 2050, Australia.
Long GV; Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia.
Wilmott JS; Melanoma Institute Australia, The University of Sydney, Sydney, NSW 2065, Australia.